ClinicalTrialsFinder
RecruitingPhase 2Phase 3NCT05749289

Application of Al18F-octreotide PET/CT in Tumors With Positive SSTR Expression

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrollment

400 participants

Start Date

Dec 20, 2022

Study Type

INTERVENTIONAL

Conditions

SSTR Positive Tumors

Summary

This is an open-label whole-body PET/CT study for investigating the value of Al18F-octreotide PET/CT in patients with SSTR positive tumors

Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Patients with suspected or clearly diagnosed SSTR positive tumors
  • signed written consent.
  • Willing and able to cooperate with all projects in this study.

Exclusion Criteria3

  • pregnancy;
  • breastfeeding;
  • any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAl18F-octreotide

Al18F-octreotide I was injected into the patients before the PET/CT scans

Locations(1)

National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College

Beijing, Chao Yang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05749289